-
Je něco špatně v tomto záznamu ?
Movement Termination of Slow-Wave Sleep-A Potential Biomarker
Y. Höller, SG. Eyjólfsdóttir, M. Rusiňák, LS. Guðmundsson, E. Trinka
Status neindexováno Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2011
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
PubMed
38790471
DOI
10.3390/brainsci14050493
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
The duration of slow-wave sleep (SWS) is related to the reported sleep quality and to the important variables of mental and physical health. The internal cues to end an episode of SWS are poorly understood. One such internal cue is the initiation of a body movement, which is detectable as electromyographic (EMG) activity in sleep-electroencephalography (EEG). In the present study, we characterized the termination of SWS episodes by movement to explore its potential as a biomarker. To this end, we characterized the relation between the occurrence of SWS termination by movement and individual characteristics (age, sex), SWS duration and spectral content, chronotype, depression, medication, overnight memory performance, and, as a potential neurological application, epilepsy. We analyzed 94 full-night EEG-EMG recordings (75/94 had confirmed epilepsy) in the video-EEG monitoring unit of the EpiCARE Centre Salzburg, Austria. Segments of SWS were counted and rated for their termination by movement or not through the visual inspection of continuous EEG and EMG recordings. Multiple linear regression was used to predict the number of SWS episodes that ended with movement by depression, chronotype, type of epilepsy (focal, generalized, no epilepsy, unclear), medication, gender, total duration of SWS, occurrence of seizures during the night, occurrence of tonic-clonic seizures during the night, and SWS frequency spectra. Furthermore, we assessed whether SWS movement termination was related to overnight memory retention. According to multiple linear regression, patients with overall longer SWS experienced more SWS episodes that ended with movement (t = 5.64; p = 0.001). No other variable was related to the proportion of SWS that ended with movement, including no epilepsy-related variable. A small sample (n = 4) of patients taking Sertraline experienced no SWS that ended with movement, which was significant compared to all other patients (t = 8.00; p < 0.001) and to n = 35 patients who did not take any medication (t = 4.22; p < 0.001). While this result was based on a small subsample and must be interpreted with caution, it warrants replication in a larger sample with and without seizures to further elucidate the role of the movement termination of SWS and its potential to serve as a biomarker for sleep continuity and for medication effects on sleep.
Faculty of Pharmaceutical Sciences University of Iceland 102 Reykjavík Iceland
Faculty of Psychology University of Akureyri 600 Akureyri Iceland
Faculty of Social Studies Masaryk University 601 77 Brno Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24012800
- 003
- CZ-PrNML
- 005
- 20240726151346.0
- 007
- ta
- 008
- 240723s2024 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/brainsci14050493 $2 doi
- 035 __
- $a (PubMed)38790471
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Höller, Yvonne $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland $1 https://orcid.org/0000000217278557
- 245 10
- $a Movement Termination of Slow-Wave Sleep-A Potential Biomarker / $c Y. Höller, SG. Eyjólfsdóttir, M. Rusiňák, LS. Guðmundsson, E. Trinka
- 520 9_
- $a The duration of slow-wave sleep (SWS) is related to the reported sleep quality and to the important variables of mental and physical health. The internal cues to end an episode of SWS are poorly understood. One such internal cue is the initiation of a body movement, which is detectable as electromyographic (EMG) activity in sleep-electroencephalography (EEG). In the present study, we characterized the termination of SWS episodes by movement to explore its potential as a biomarker. To this end, we characterized the relation between the occurrence of SWS termination by movement and individual characteristics (age, sex), SWS duration and spectral content, chronotype, depression, medication, overnight memory performance, and, as a potential neurological application, epilepsy. We analyzed 94 full-night EEG-EMG recordings (75/94 had confirmed epilepsy) in the video-EEG monitoring unit of the EpiCARE Centre Salzburg, Austria. Segments of SWS were counted and rated for their termination by movement or not through the visual inspection of continuous EEG and EMG recordings. Multiple linear regression was used to predict the number of SWS episodes that ended with movement by depression, chronotype, type of epilepsy (focal, generalized, no epilepsy, unclear), medication, gender, total duration of SWS, occurrence of seizures during the night, occurrence of tonic-clonic seizures during the night, and SWS frequency spectra. Furthermore, we assessed whether SWS movement termination was related to overnight memory retention. According to multiple linear regression, patients with overall longer SWS experienced more SWS episodes that ended with movement (t = 5.64; p = 0.001). No other variable was related to the proportion of SWS that ended with movement, including no epilepsy-related variable. A small sample (n = 4) of patients taking Sertraline experienced no SWS that ended with movement, which was significant compared to all other patients (t = 8.00; p < 0.001) and to n = 35 patients who did not take any medication (t = 4.22; p < 0.001). While this result was based on a small subsample and must be interpreted with caution, it warrants replication in a larger sample with and without seizures to further elucidate the role of the movement termination of SWS and its potential to serve as a biomarker for sleep continuity and for medication effects on sleep.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Eyjólfsdóttir, Stefanía Guðrún $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland
- 700 1_
- $a Rusiňák, Matej $u Faculty of Psychology, University of Akureyri, 600 Akureyri, Iceland $u Faculty of Social Studies, Masaryk University, 601 77 Brno, Czech Republic
- 700 1_
- $a Guðmundsson, Lárus Steinþór $u Faculty of Pharmaceutical Sciences, University of Iceland, 102 Reykjavík, Iceland $1 https://orcid.org/0000000346601111
- 700 1_
- $a Trinka, Eugen $u Department of Neurology, Neurointensive Care and Neurorehabilitation, Christian-Doppler University Hospital, Paracelsus Medical University, Centre for Neuroscience Salzburg, Member of the European Reference Network, EpiCARE, 5020 Salzburg, Austria $u Neuroscience Institute, Christian-Doppler University Hospital, Centre for Cognitive Neuroscience, 5020 Salzburg, Austria
- 773 0_
- $w MED00198694 $t Brain sciences $x 2076-3425 $g Roč. 14, č. 5 (2024)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/38790471 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240723 $b ABA008
- 991 __
- $a 20240726151339 $b ABA008
- 999 __
- $a ok $b bmc $g 2125478 $s 1224663
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 14 $c 5 $e 20240513 $i 2076-3425 $m Brain sciences $n Brain Sci $x MED00198694
- LZP __
- $a Pubmed-20240723